Thiago Wendt Viola1, Breno Sanvicente-Vieira, Bruno Kluwe-Schiavon, Leonardo Melo Rothmann, João Vítor Nóbrega E Mélo-Pereira, Carla Bicca, João Paulo Ottolia Niederauer, Joy Schmitz, Rodrigo Grassi-Oliveira. 1. Pontifical Catholic University of Rio Grande do Sul (PUCRS), Developmental Cognitive Neuroscience Lab, Porto Alegre, RS, Brazil (TWV, LMR, JVNMP, CB, JPN, RG-O); Experimental and Clinical Pharmacopsychology Laboratory, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland (BK-S); Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, TX (JS); Pontifical Catholic University of Rio de Janeiro (PUC-Rio), Department of Psychology, Rio de Janeiro, RJ, Brazil (BS-V).
Abstract
BACKGROUND: The effects of cannabis on clinical outcomes of treatment services for other drug use disorders remains unclear. The primary aim of the current study was to investigate the effects of recent cannabis consumption on the severity of cocaine withdrawal and depressive symptoms during a 3-week inpatient treatment program for women with cocaine use disorder. The second goal of this study was to test the effect of recent alcohol or tobacco use on the aforementioned outcomes. METHODS: This was a longitudinal study with 2 assessment time points: at enrollment and upon discharge from a medically managed intensive inpatient unit. The sample was composed of 214 early abstinence females with cocaine use disorder. Cocaine withdrawal and depressive symptoms were measured using the Cocaine Selective Severity Assessment (CSSA) and the Beck Depressive Inventory (BDI-II). Recent substance use was evaluated using the Addiction Severity Index (ASI-6). RESULTS: Patients with cocaine use disorder and with frequent recent cannabis use reported higher severity of cocaine withdrawal and depressive symptoms after 3 weeks of inpatient treatment. Neither recent alcohol nor tobacco use was associated with increased CSSA or BDI outcomes, suggesting these substances play a minor role compared to recent cannabis use in affecting withdrawal-related symptoms. CONCLUSIONS: The assessment of recent cannabis use may help identify patients in need of additional treatment to manage severe cocaine withdrawal symptoms and depressive symptoms during early abstinence.
BACKGROUND: The effects of cannabis on clinical outcomes of treatment services for other drug use disorders remains unclear. The primary aim of the current study was to investigate the effects of recent cannabis consumption on the severity of cocaine withdrawal and depressive symptoms during a 3-week inpatient treatment program for women with cocaine use disorder. The second goal of this study was to test the effect of recent alcohol or tobacco use on the aforementioned outcomes. METHODS: This was a longitudinal study with 2 assessment time points: at enrollment and upon discharge from a medically managed intensive inpatient unit. The sample was composed of 214 early abstinence females with cocaine use disorder. Cocaine withdrawal and depressive symptoms were measured using the Cocaine Selective Severity Assessment (CSSA) and the Beck Depressive Inventory (BDI-II). Recent substance use was evaluated using the Addiction Severity Index (ASI-6). RESULTS:Patients with cocaine use disorder and with frequent recent cannabis use reported higher severity of cocaine withdrawal and depressive symptoms after 3 weeks of inpatient treatment. Neither recent alcohol nor tobacco use was associated with increased CSSA or BDI outcomes, suggesting these substances play a minor role compared to recent cannabis use in affecting withdrawal-related symptoms. CONCLUSIONS: The assessment of recent cannabis use may help identify patients in need of additional treatment to manage severe cocainewithdrawal symptoms and depressive symptoms during early abstinence.
Authors: Gregory J DiGirolamo; Gerardo Gonzalez; David Smelson; Nathan Guevremont; Michael I Andre; Pooja O Patnaik; Zachary R Zaniewski Journal: J Dual Diagn Date: 2017-11-09
Authors: Stewart A Shankman; Carter J Funkhouser; Daniel N Klein; Joanne Davila; Debra Lerner; Danelle Hee Journal: Int J Methods Psychiatr Res Date: 2017-10-16 Impact factor: 4.035
Authors: Efrat Aharonovich; Fatima Garawi; Adam Bisaga; Daniel Brooks; Wilfrid N Raby; Eric Rubin; Edward V Nunes; Frances R Levin Journal: Am J Drug Alcohol Abuse Date: 2006 Impact factor: 3.829
Authors: Giovanni Battistella; Eleonora Fornari; Aurélien Thomas; Jean-Frédéric Mall; Haithem Chtioui; Monique Appenzeller; Jean-Marie Annoni; Bernard Favrat; Philippe Maeder; Christian Giroud Journal: PLoS One Date: 2013-01-02 Impact factor: 3.240
Authors: Lucca Pizzato Tondo; Thiago Wendt Viola; Gabriel R Fries; Bruno Kluwe-Schiavon; Leonardo Mello Rothmann; Renata Cupertino; Pedro Ferreira; Alexandre Rosa Franco; Scott D Lane; Laura Stertz; Zhongming Zhao; Ruifeng Hu; Thomas Meyer; Joy M Schmitz; Consuelo Walss-Bass; Rodrigo Grassi-Oliveira Journal: Transl Psychiatry Date: 2021-04-29 Impact factor: 6.222